Jean-David Bouaziz
Jean-David Bouaziz is an expert in Dermatology at Hôpital Saint-Louis (France). As of October 2026, ScienceLeadR ranks Jean-David Bouaziz in the top 1% of experts worldwide for Dermatitis, Sexually Transmitted Diseases and Hypersensitivity. Jean-David Bouaziz has authored 570 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 11 of them ongoing. SLR score: 2,024 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Immunology - Hematology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 570
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Trophoblast Extracellular Vesicles Rewire Immunity: A Symptom-Relief Avenue for Recessive Dystrophic Epidermolysis Bullosa. PMID 42782177 — cells, extracellular vesicles, pregnancy, epidermolysis bullosa dystrophica, monocytes, trophoblasts, microscopy, electron, scanning transmission, transport vesicles, immunity, epidermolysis bullosa | J Extracell Vesicles | 2026 | 0 |
| Sweet syndrome following cervicofacial rhytidectomy: A case report. PMID 42633396 — sweet syndrome | JPRAS Open | 2026 | 0 |
| Durable remission after allogeneic transplantation despite residual blood disease in Sézary syndrome. PMID 42615645 — sexually transmitted diseases, blood, sezary syndrome, transplantation, homologous, skin diseases, hematologic diseases, transplantation | J Eur Acad Dermatol Venereol | 2026 | 0 |
| The spectrum of eosinophilic cellulitis (Wells' syndrome): new insights based on 114 cases. PMID 42551694 — hypersensitivity, adrenal cortex hormones, cellulitis, eosinophils, therapeutics | J Allergy Clin Immunol Pract | 2026 | 0 |
| PHYTOCERAMIDES AND 6-HYDROXYCERAMIDES DEFICIENCY CORRELATES WITH BARRIER FUNCTION ALTERATION IN ATOPIC DERMATITIS SKIN. PMID 42480860 — skin, dermatitis, lipidomics, dermatology, dermatitis, atopic | J Invest Dermatol | 2026 | 0 |
Clinical Studies 25
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
11 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Multicenter Randomized Double Blind Placebo Controlled Phase 2a Study With an Open Label Extension Evaluating the Efficacy and Safety of VENT 03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus 2024-520098-12-00 — lupus erythematosus, cutaneous, safety, lupus erythematosus, systemic | Phase 2 | Recruiting | 2026 |
| A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in participants aged 12 years and older with moderate to severe atopic dermatitis 2023-508096-36-00 — injections, safety, dermatitis, maintenance, aged, therapeutics, injections, subcutaneous, dermatitis, atopic | Phase 3 | Active not recruiting | 2024 |
| Long Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinical trials 2023-506548-18-00 — safety, dermatitis, dermatitis, atopic | Phase 2/Phase 3 | Not yet recruiting | 2022 |
| A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum 2024-514306-31-00 — skin, safety, multiple chronic conditions, therapeutics, pyoderma, pyoderma gangrenosum | Phase 3 | Recruiting | 2025 |
| A Long Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (CLE) (AMETHYST LTE) 2023-504863-17-00 — injections, lupus erythematosus, cutaneous, safety, signs and symptoms, therapeutics, antimalarials | Phase 3 | Recruiting | 2024 |
LeadR Networks
Main global connection map